Search

Background: As the COVID-19 pandemic continues to unfold, increasing numbers of Canadians have self-medicated with ivermectin, an antiparasitic drug used to treat infections and infestations in humans and livestock. This is despite a lack of goodquality evidence for its efficacy in preventing and treating infection with SARS CoV-2. Concerns over unsafe use of ivermectin prompted a review of calls to the British Columbia Drug and Poison Information Centre. Methods: We performed a descriptive analysis of calls received from 1 January 2018 to 11 October 2021 about exposure to ivermectin and related compounds. Results: The BC Drug and Poison Information Centre received 50 calls concerning exposure to ivermectin and related compounds during the period we studied. Prior to the COVID-19 pandemic, 23 calls were made, and all but one were unintentional exposures. The first ivermectin call referencing COVID-19 was received in March 2021, after which call frequency increased, leading to 27 more calls, of which 19 were intentional exposures to ivermectin referencing COVID-19. Of these calls, 11 concerned veterinary-grade ivermectin, and where doses were calculable, at 0.147-11.91 mg/kg, they were above the 0.15-0.2mg/kg therapeutic dose for most approved human uses. Three exposures were asymptomatic, 11 were considered to have minor effects, 1 was moderate, 4 were symptomatic but considered unrelated to ivermectin, and in 1 case symptoms were not recorded. Conclusions: The use of ivermectin to prevent or treat COVID-19 is occurring in British Columbia, and both human and veterinary formulations are being ingested. Our case review suggests that these exposures occur most frequently in more agricultural regions, where the portion of adults vaccinated against COVID-19 has been lower and the portion infected higher than elsewhere in the province. [ABSTRACT FROM AUTHOR]